Portal for life science/healthcare startups
  • Home
    • English Top
    • 日本語トップ
  • Table of Contents (English)
    • Business Setup & Operations >
      • Startup Visa
      • setup corporation, office in Japan
      • Company establishment
      • Life Science Hub, Startup Hub
    • Public Support >
      • List of Public Support Organizations
      • Public Support in Yokohama city
      • Academia-Based Startup Support Guide
      • Mediso free consultation service
    • Regulatory & Compliance >
      • PMDA consultation
      • regulatory considerations when using person infformation
      • Guide to Selecting Regulatory Affairs Staff and Consultants
      • Expedited Review Systems for Pharmaceuticals
      • Guidelines for Establishing Generic Drug Names
      • Combination Products, Combination Medical Devices, Kit Products, Combination Drugs
    • Medical Device, IVD >
      • IVD, LDT, RUO
      • DMAH: Designated Marketing Authorization Holder-Summary Ver.
      • DMAH: Designated Marketing Authorization Holder
      • Combination Products, Combination Medical Devices, Kit Products, Kit Components, Assortment Products
      • How to determine if a product is a medical device
      • medical device classification for combined products
      • medical device class
      • how to confirm JMDN of medical device
      • medical device & IVD reimbursement-Summary Ver.
      • medical device & IVD reimbursemenet
      • insurance reimbursement for SaMD
      • Comparison of Medical Device Definitions: Japan, US, & EU
      • Companion Diagnostics and Gene Panel Testing
    • Pharmaceutical, regenerative medicine >
      • How to determine if a product is a Pharmaceutical Drug
      • Advanced Medical Care System
      • Over-The-Counter (OTC) Drug
      • References on Reimbursement (Cost Calculation) for Regenerative Medical Products
    • Healthcare & Caretech Products >
      • guidance for non medical services
      • Therapeutic Orthoses and Assistive Devices
      • Cosmetics and Quasi-Drugs
      • Overseas Expansion of Non-Medical Device Products as Medical Devices: Learning from the Case of PARO
    • Funding, Partnering & Networking >
      • Utilization of Public Grants and Subsidies
      • J-Ships
      • Partnering
    • Intellectual Property >
      • patent or trade secret?
      • employee invention
      • Matching of Patents Held by Startups and Individuals
    • Legal & Contracts >
      • References for Contracts
      • Guide to Industry-Academia Collaboration Agreements for Academic Researchers
    • Academia & Tech Transfer
    • Licensing, partnering >
      • Introducing Seeds to Pharmaceutical Companies
      • Incentives (Returns) to Licensor Universities
    • References in English
  • コンテンツ一覧
    • 事業設立・運営 >
      • 法人設立
      • ライフサイエンスハブ、スタートアップハブ
    • 公的支援 >
      • 公的支援機関リスト
      • 大学発スタートアップ支援機関・プログラムガイド
      • AMED Medical IP Desk
      • MEDISO活用のススメ
    • 薬事・規制関連 >
      • PMDA RS相談活用のススメ
      • 薬事スタッフ・コンサル選定ガイド
      • 都道府県薬務課一覧
      • コンビネーション製品、組合せ医療機器、キット製品、組合せ医薬品
    • 医薬品、再生医療等製品 >
      • 医薬品の該当性確認方法
      • 医薬品一般的名称設定のガイドライン
      • 医薬品、医療機器等の開発に当たって、参照したい資料
      • 先進医療制度
      • 一般用医薬品(OTC)
      • コンパニオン診断薬と遺伝子パネル検査
      • 再生医療等製品の保険償還(原価計算)に関する参考情報
    • 医療機器、体外診断用医薬品 >
      • 体外診、ラボ開発検査、研究用試薬
      • 医療機器該当性確認ガイド
      • 医療機器と非医療機器の機能が複合した製品は?
      • 医療機器の一般的名称と確認方法
      • 医療機器のクラス分類
      • 医療機器・体外診の保険収載
      • SaMDの保険収載
    • ヘルスケア・ケアテック >
      • 非医療分野の検査サービスを展開する際に注意すべきポイント
      • 治療用装具と補装具
      • 化粧品及び医薬部外品
      • 医療機器とするか、非医療機器とするか
    • 資金調達 >
      • 公的な助成金、補助金の活用
      • 特定投資家向け銘柄制度(J-Ships)
      • パートナリング
      • アカデミア研究者がPIとして応募可能なグラントリスト
      • 海外在住の日本人研究者が日本の助成金を獲得する方法
    • 知的財産 >
      • 特許か?営業秘密か?
      • 職務発明:アカデミア・公的研究機関に所属する研究者が注意すべきポ
      • スタートアップや個人が保有する特許のマッチング
      • ライセンスを受けた大学へのインセンティブ(還元)について
    • 法務・契約 >
      • 契約関連で参考になる公的機関の資料
      • 個人情報を利用する製品開発時の 留意すべき法規制
    • アカデミア、技術移転 >
      • アカデミア研究者のための産学連携契約ガイド
    • ライセンシング、パートナリング >
      • 製薬企業等へのシーズ紹介
    • 海外展開 >
      • 米国展開(主に医療機器)に、読むと役立つ情報リスト
      • 米国FDAにおける、医療機器該当性の確認ステップ
      • 米国における、医療機器の申請データ・試験計画の相談方法((Pre-Submission/Q-Submission
      • 公的機関の海外展開支援
      • 横浜市の公的支援サービス
      • JETROを徹底活用しよう
      • 日米欧での医療機器定義の比較
      • 簡略審査(審査の迅速化)
      • 海外規制等の情報収集
      • 非医療機器製品の海外での医療機器展開
    • オーストラリア >
      • オーストラリア研究開発優遇税制の概要
      • オーストラリア研究開発優遇税制の適用を受けるには
      • オーストラリアでの主要イベント
      • R&D関連の公的機関
      • オーストラリア助成金情報

A Guide to Industry-Academia
Collaboration Agreements

Key points for researchers at universities and research institutions when contracting with companies.

This content is intended for a Japanese audience. Please refer to the original Japanese text for accuracy as this has been machine-translated. Foreign companies doing business in Japan will need support from Japanese-speaking staff due to local language requirements and business practices.

@K.Kamitani

Table of Contents

  • 1. Introduction
  • 2. Non-Disclosure Agreement (NDA)
  • 3. Joint Research Agreement
  • 4. Joint Application Agreement
  • 5. License Agreement
  • 6. Intellectual Property (IP)
  • 7. Reference Materials
  • 8. Collaborating with the TLO

@K.Kamitani

1. Introduction

Collaboration with companies is essential for the social implementation of research outcomes. However, there are fundamental differences in the positions and interests between academia, which emphasizes the publication of results, and companies, which aim for exclusive use in their business.

University Company
Nature of Institution Non-profit For-profit
Purpose of Joint Research Academic research Business promotion
Intellectual Property (IP) Request for royalties
Desire to license to others
Prefers royalty-free
Restricts licensing to others
Confidentiality & Publication Confidentiality is difficult
Desire to publish papers
Confidentiality is crucial
Publication is not a priority

It is important to understand this conflicting structure and approach negotiations based on this guide to avoid disadvantageous agreements for academia.

@K.Kamitani

2. Non-Disclosure Agreement (NDA)

An agreement signed before full-scale collaborations like joint research, to exchange and discuss technical information from both parties.

Key Points for Academics (Researchers)
  • Balance Risks and Returns: University information, such as pre-publication data, can lead to significant disadvantages if leaked. Be cautious, as some companies (e.g., in pharmaceuticals) often conduct initial evaluations without an NDA.
  • Limit the Definition of Confidential Information: Negotiate to limit confidential information to only what is explicitly marked (e.g., with "Confidential"), clarifying the scope of what needs to be managed.
  • Avoid Information Contamination: There's a risk that company information will mix with your own knowledge, restricting your research. Avoid receiving unnecessary information.
  • Clarify the Purpose: Specifically define the purpose for which confidential information can be used to reduce the risk of misuse.
  • Beware of Confidentiality Period and Auto-Renewal: Avoid unnecessarily long periods, which increase the risk of accidental leaks. Auto-renewal clauses can also heighten this risk.
  • Ensure Thorough Information Management: Received confidential information must be strictly managed at the lab level, such as by storing it in separate disks or folders from your own information.
  • Promptly Return or Destroy Information After Termination: Continuing to hold onto information only increases the risk of leaks with no benefit.

@K.Kamitani

3. Joint Research Agreement

This is the core agreement in industry-academia collaboration, defining the research purpose, content, duration, costs, and handling of outcomes when conducting R&D with a company.

Key Points for Academics (Researchers)
  • Reflect the "Value of Knowledge" in Research Costs: Negotiate to properly account not just for direct costs (like materials), but also for researchers' intellectual contributions and strategic expenses that support the university's collaboration activities.
  • Clarify IP Rights Ownership: Specifically define the ownership share of jointly created inventions (shared patents), cost allocation, the scope of licensing rights to the company, and procedures if the company chooses not to exploit the patent.
  • Establish Rules for Publishing Research Results: Set reasonable terms for notifying the company before publishing papers and for the period the company can request a delay for patent filing, ensuring it doesn't hinder academic activities.
  • Specify the Research Plan: Clearly defining the research content and division of roles helps prevent future troubles and serves as a basis for determining inventorship.
  • Create and Agree on a Final Report: It is crucial to create a mutually confirmed final report to clarify the scope of research outcomes and prevent disputes. Daily record-keeping in research notebooks is recommended for this.
  • Give Special Consideration to Student Participation: Students are not university employees and cannot be subjected to excessive obligations. Their free will must be respected, while obtaining the minimum necessary consent (e.g., confidentiality, assignment of inventions to the university) to fulfill the contract with the company.

@K.Kamitani

4. Joint Application Agreement

An agreement that defines procedures, cost-sharing, and ownership shares when a university and a company jointly file a patent for an invention created through joint research.

Key Points for Academics (Researchers)
  • Ownership Share: It is crucial to establish a fair ownership ratio based on the contribution to the invention. Avoid defaulting to 50:50 without negotiation based on actual contributions.
  • Cost Sharing: Clearly define how costs from application to maintenance (e.g., patent attorney fees, patent office fees) will be divided.
  • Non-Exercise of Rights: Define what happens if the other party does not exercise its rights (e.g., not filing overseas, non-payment of annuities) to avoid the risk of losing the patent.
  • Licensing to Third Parties: A shared patent cannot be licensed to a third party without the other owner's consent. It is desirable to define the conditions under which licensing is permissible.

@K.Kamitani

5. License Agreement

An agreement where the university grants a company a license to use (practice) its intellectual property, such as patents, in its business.

Key Points for Academics (Researchers)
  • Scope of License: Clearly specify the content of the licensed rights (e.g., patent numbers), duration, and territory.
  • Exclusive vs. Non-Exclusive: Define whether the license is exclusive to one company or non-exclusive (allowing licenses to multiple companies). Exclusive licenses can command higher royalties.
  • License Fees (Royalties): Clarify the calculation method (e.g., percentage of sales, flat fee) and payment terms. It is important to set a fair price commensurate with market value.
  • Handling of Non-Use: To prevent the technology from being "shelved," it is important to include a clause on whether the license can be revoked if the company does not use the patent without a valid reason.

@K.Kamitani

6. Intellectual Property (IP)

In all the agreements discussed so far, the most critical common issue is the handling of "Intellectual Property."

Companies want to exclusively secure research results as intellectual property to maintain a competitive advantage. In contrast, academia desires the freedom to publish results and use them for further research.

It is necessary to always approach contract negotiations with an IP perspective to avoid falling into a disadvantageous situation where the terms are dictated by the company's logic, leading to research restrictions or loss of potential benefits.

@K.Kamitani

7. Reference Materials

  • Guidelines for Enhancing Joint Research through Industry-Academia-Government Collaboration
    METI / MEXT
    A comprehensive guideline outlining the basic principles for universities and companies regarding joint research costs and IP handling to qualitatively transform Japan's industry-academia collaboration. https://www.meti.go.jp/policy/innovation_corp/guideline.html
  • University IP Governance Guidelines
    Intellectual Property Strategy Headquarters
    Explains the governance system for universities to build and execute IP strategies organization-wide. Useful for understanding a university's IP policy. https://www.kantei.go.jp/jp/singi/titeki2/tyousakai/daigaku_gov/governance_guideline.html
  • Open Innovation Portal Site
    Japan Patent Office (JPO)
    A portal site offering comprehensive information useful for industry-academia and startup collaborations, including contract templates, manuals, and case studies. https://www.jpo.go.jp/support/general/open-innovation-portal/index.html
  • Research on Patent Right Ownership and Licensing in University-Industry Collaborations
    Kanto Branch of Japan Patent Attorneys Association (JPAA)
    This report summarizes a survey, analysis, and challenges regarding patent ownership and licensing in industry-academia collaborations from the expert perspective of patent attorneys. https://media.jpaa-kanto.jp/sangakurenkeitokkyoken/

@K.Kamitani

8. Collaborating with the TLO

Researchers Should Not Negotiate Alone

Contract negotiations with companies are led by the industry-academia collaboration division, not by individual researchers. This is because inventions arising from university research are almost always considered "work-for-hire" inventions, with the rights belonging to the university, not the individual inventor.

With government support, the infrastructure of university Technology Licensing Organizations (TLOs) has been rapidly developing. A TLO is a professional group that provides comprehensive support to researchers, from IP strategy and patent filing to social implementation through corporate partnerships.

Frequently consulting with your university's TLO, starting from the patent consultation stage, is the most crucial point for a smooth process.

@K.Kamitani

Home
About JPRO
Table of Contents
​
​オフィス概要
​コンテンツ一覧
Ⓒ2025 JPRO
JPRO is a Japan-based business incubator for startups. 
Our approach is unique because our primary focus is on enabling startup self-sufficiency. Our core mission is to help startups optimize their time and cost-efficiency, ensuring they avoid unnecessary expenses and delays. We achieve this by providing centralized access to essential, high quality information—all completely free of charge.
The reliability of our content is exceptionally high, as our information is sourced directly from public institutions and the advice mirrors what we provide in our official advisory roles within these very organizations.
​"You'll likely gain a clear understanding of what needs to be done, enabling you to manage many aspects of your business in-house."
  • Home
    • English Top
    • 日本語トップ
  • Table of Contents (English)
    • Business Setup & Operations >
      • Startup Visa
      • setup corporation, office in Japan
      • Company establishment
      • Life Science Hub, Startup Hub
    • Public Support >
      • List of Public Support Organizations
      • Public Support in Yokohama city
      • Academia-Based Startup Support Guide
      • Mediso free consultation service
    • Regulatory & Compliance >
      • PMDA consultation
      • regulatory considerations when using person infformation
      • Guide to Selecting Regulatory Affairs Staff and Consultants
      • Expedited Review Systems for Pharmaceuticals
      • Guidelines for Establishing Generic Drug Names
      • Combination Products, Combination Medical Devices, Kit Products, Combination Drugs
    • Medical Device, IVD >
      • IVD, LDT, RUO
      • DMAH: Designated Marketing Authorization Holder-Summary Ver.
      • DMAH: Designated Marketing Authorization Holder
      • Combination Products, Combination Medical Devices, Kit Products, Kit Components, Assortment Products
      • How to determine if a product is a medical device
      • medical device classification for combined products
      • medical device class
      • how to confirm JMDN of medical device
      • medical device & IVD reimbursement-Summary Ver.
      • medical device & IVD reimbursemenet
      • insurance reimbursement for SaMD
      • Comparison of Medical Device Definitions: Japan, US, & EU
      • Companion Diagnostics and Gene Panel Testing
    • Pharmaceutical, regenerative medicine >
      • How to determine if a product is a Pharmaceutical Drug
      • Advanced Medical Care System
      • Over-The-Counter (OTC) Drug
      • References on Reimbursement (Cost Calculation) for Regenerative Medical Products
    • Healthcare & Caretech Products >
      • guidance for non medical services
      • Therapeutic Orthoses and Assistive Devices
      • Cosmetics and Quasi-Drugs
      • Overseas Expansion of Non-Medical Device Products as Medical Devices: Learning from the Case of PARO
    • Funding, Partnering & Networking >
      • Utilization of Public Grants and Subsidies
      • J-Ships
      • Partnering
    • Intellectual Property >
      • patent or trade secret?
      • employee invention
      • Matching of Patents Held by Startups and Individuals
    • Legal & Contracts >
      • References for Contracts
      • Guide to Industry-Academia Collaboration Agreements for Academic Researchers
    • Academia & Tech Transfer
    • Licensing, partnering >
      • Introducing Seeds to Pharmaceutical Companies
      • Incentives (Returns) to Licensor Universities
    • References in English
  • コンテンツ一覧
    • 事業設立・運営 >
      • 法人設立
      • ライフサイエンスハブ、スタートアップハブ
    • 公的支援 >
      • 公的支援機関リスト
      • 大学発スタートアップ支援機関・プログラムガイド
      • AMED Medical IP Desk
      • MEDISO活用のススメ
    • 薬事・規制関連 >
      • PMDA RS相談活用のススメ
      • 薬事スタッフ・コンサル選定ガイド
      • 都道府県薬務課一覧
      • コンビネーション製品、組合せ医療機器、キット製品、組合せ医薬品
    • 医薬品、再生医療等製品 >
      • 医薬品の該当性確認方法
      • 医薬品一般的名称設定のガイドライン
      • 医薬品、医療機器等の開発に当たって、参照したい資料
      • 先進医療制度
      • 一般用医薬品(OTC)
      • コンパニオン診断薬と遺伝子パネル検査
      • 再生医療等製品の保険償還(原価計算)に関する参考情報
    • 医療機器、体外診断用医薬品 >
      • 体外診、ラボ開発検査、研究用試薬
      • 医療機器該当性確認ガイド
      • 医療機器と非医療機器の機能が複合した製品は?
      • 医療機器の一般的名称と確認方法
      • 医療機器のクラス分類
      • 医療機器・体外診の保険収載
      • SaMDの保険収載
    • ヘルスケア・ケアテック >
      • 非医療分野の検査サービスを展開する際に注意すべきポイント
      • 治療用装具と補装具
      • 化粧品及び医薬部外品
      • 医療機器とするか、非医療機器とするか
    • 資金調達 >
      • 公的な助成金、補助金の活用
      • 特定投資家向け銘柄制度(J-Ships)
      • パートナリング
      • アカデミア研究者がPIとして応募可能なグラントリスト
      • 海外在住の日本人研究者が日本の助成金を獲得する方法
    • 知的財産 >
      • 特許か?営業秘密か?
      • 職務発明:アカデミア・公的研究機関に所属する研究者が注意すべきポ
      • スタートアップや個人が保有する特許のマッチング
      • ライセンスを受けた大学へのインセンティブ(還元)について
    • 法務・契約 >
      • 契約関連で参考になる公的機関の資料
      • 個人情報を利用する製品開発時の 留意すべき法規制
    • アカデミア、技術移転 >
      • アカデミア研究者のための産学連携契約ガイド
    • ライセンシング、パートナリング >
      • 製薬企業等へのシーズ紹介
    • 海外展開 >
      • 米国展開(主に医療機器)に、読むと役立つ情報リスト
      • 米国FDAにおける、医療機器該当性の確認ステップ
      • 米国における、医療機器の申請データ・試験計画の相談方法((Pre-Submission/Q-Submission
      • 公的機関の海外展開支援
      • 横浜市の公的支援サービス
      • JETROを徹底活用しよう
      • 日米欧での医療機器定義の比較
      • 簡略審査(審査の迅速化)
      • 海外規制等の情報収集
      • 非医療機器製品の海外での医療機器展開
    • オーストラリア >
      • オーストラリア研究開発優遇税制の概要
      • オーストラリア研究開発優遇税制の適用を受けるには
      • オーストラリアでの主要イベント
      • R&D関連の公的機関
      • オーストラリア助成金情報